Video

Scott Solomon from Brigham and Women's Hospital: Building Momentum to Help Heart Failure Patients

Author(s):

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

One such medication being studied in this effort is sacubitril/valsartan, also known as entresto. Scott David Solomon, MD, from Brigham & Women's Hospital and Harvard Medical School discussed the results of the Paradigm-HF trial which studied how the medication can help even "stable" heart failure patients. Solomon said the results of the study showed the benefit of this medication would work when compared to other patients including those ACE inhibitors or ARBs.

Related Videos
Experts' Perspectives: Top Stories in Cardiology for 2024
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
© 2025 MJH Life Sciences

All rights reserved.